Development of orphan and ultra orphan drugs to prevent, diagnose and treat rare diseases is very challenging due to its niche nature. On the other hand, rare diseases show the potential of less intense competition, faster and less expensive development, and lower marketing spend on a small, highly motivated audience.
Fleming Europe invites you to Orphan Drug Congress 2011. We have gathered worldwide Pharma specialists who will share their knowledge with you. Hear them speak about regulatory landscape for orphan drug development, discuss how to overcome challenges of orphan drug development and commercialization and examine marketing authorization challenges. Come and listen to real life case studies, discover innovative approaches and benefit from interactive discussions with your peers to benchmark your experiences.
At this conference, you will have the chance to meet true market leaders, top speakers and real experts from pharmaceutical industry. Do not miss the opportunity to gain new knowledge and join us at this event of the year.
Key speakers:
Geoff McDonough, Genzyme, Belgium, President Genzyme Europe
Ed Mascioli, Pfizer, USA, VP, Head of the Orphan and Genetic Diseases Research Unit
Bo Jesper Hansen, Swedish Orphan Biovitrum, Switzerland, Executive Chairman
Robert Sebbag, Sanofi Aventis, France, Vice President Access to Medicines
Erin Gainer, HRA Pharma, France, CEO
Segolene Ayme, OrphaNet, France, Founder & President
James K. Lennertz, BioMarin Europe, UK, (TBC) Vice President & General Manager